Search Results

leon-nanodrugs GmbH (“LEON”), the leading enabler of nano technology for the pharmaceutical industry, announced today the appointment of Dr. Hans Frickel as CEO, effective July 1, 2023. Dr. Hans Frickel, a trained pharmacist and industrial manager, brings more than 20 years of experience in strategic and operational leadership roles across the entire value chain of pharmaceuticals and medical devices.

Barinthus Biotherapeutics plc, formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer.

NurExone Biologic Inc., a biopharmaceutical company, announced the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that Dane Leone, CFA, has joined Xencor as senior vice president, corporate strategy.

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.